NBRV

Nabriva Therapeutics plc [NBRV] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

NBRV Stock Summary

In the News

06:20 29 Mar 2024 NBRV

7 Stocks to Sell as Banks Melt Down

Peruse the Internet for investment guidance and you're likely to hear the adage that you shouldn't consider stocks to sell when faced with volatility. Rather, you should buy up assets and securities when there's blood on the streets.

02:18 29 Mar 2024 NBRV

Nabriva (NBRV) Posts Positive Data From Cystic Fibrosis Study

Nabriva (NBRV) posts positive top-line data from the phase I study evaluating oral and intravenous Xenleta (lefamulin) in adult patients with cystic fibrosis. Shares down.

08:20 29 Mar 2024 NBRV

Nabriva's stock is up after sharing antibiotic news

Shares of Nabriva Therapeutics Plc NBRV, were up 13.8% in premarket trading on Monday after the company said in a news release it had positive data from a Phase 1 clinical trial assessing its antibiotic as a treatment for cystic fibrosis. The drug, Xenleta, is approved to treat community-acquired bacterial pneumonia.

07:40 29 Mar 2024 NBRV

Nabriva Therapeutics plc (NBRV) Q3 2022 Earnings Call Transcript

Nabriva Therapeutics plc (NASDAQ:NBRV ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Daniel Dolan - CFO Theodore Schroeder - CEO Conference Call Participants Carl Byrnes - Northland Capital Markets Ed Arce - H.C. Wainwright Operator Welcome to the Nabriva Therapeutics Third Quarter 2022 Financial Results Call and Corporate Update.

07:01 29 Mar 2024 NBRV

Nabriva Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Highlights on November 10, 2022

DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its third quarter financial results along with recent company highlights after the close of the U.S. financial markets on Thursday, November 10, 2022. Nabriva's management will host a conference call at 4:30 p.m. ET to discuss the financial results and recent corporate highlights.

11:30 29 Mar 2024 NBRV

What Is Going on With Nabriva Therapeutics (NBRV) Stock Today?

Source: iQoncept / Shutterstock Nabriva Therapeutics (NASDAQ: NBRV ) stock caught the attention of traders on Friday after shares surged in price this morning. However, not all is as it seems.

06:00 29 Mar 2024 NBRV

Buying Penny Stocks Today? What You Need to Know

Here's what you need to know about trading penny stocks on September 16th The post Buying Penny Stocks Today? What You Need to Know  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

08:05 29 Mar 2024 NBRV

Nabriva Therapeutics (NBRV) Stock: 1-For-25 Reverse Stock Split Announced

Nabriva Therapeutics (NBRV) announces it will effect a 1-for-25 reverse stock split. These are the details.

07:01 29 Mar 2024 NBRV

Nabriva Therapeutics Announces Date of 1-for-25 Reverse Stock Split

DUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 15, 2022 (GLOBE NEWSWIRE) --  Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will effect a 1-for-25 reverse stock split of its outstanding ordinary shares, which will be effective for trading purposes on the Nasdaq Capital Market as of the commencement of trading on September 16, 2022.

01:29 29 Mar 2024 NBRV

All You Need to Know About Nabriva Therapeutics AG (NBRV) Rating Upgrade to Buy

Nabriva Therapeutics AG (NBRV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

NBRV Financial details

Company Rating
Neutral
Market Cap
4.55M
Income
-54.49M
Revenue
35.59M
Book val./share
-1.36
Cash/share
0.56
Dividend
-
Dividend %
-
Employees
39
Optionable
No
Shortable
Yes
Earnings
10 Aug 2023
P/E
-0.08
Forward P/E
-
PEG
0.03
P/S
0.13
P/B
-1.04
P/C
-
P/FCF
-0.17
Quick Ratio
0.44
Current Ratio
0.85
Debt / Equity
-0.12
LT Debt / Equity
-0.08
-
-
EPS (TTM)
-19.93
EPS next Y
-
EPS next Q
-
EPS this Y
-25.25%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-48.08%
Revenue last 5Y
40.56%
Revenue Q/Q
-27.29%
EPS Q/Q
-66.43%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0.12%
Inst Trans
0.56%
ROA
-224%
ROE
-368%
ROC
14.32%
Gross Margin
17%
Oper. Margin
-147%
Profit Margin
-153%
Payout
-
Shs Outstand
3.2M
Shs Float
0
-
-
-
-
Target Price
1
52W Range
1.215-8.45
52W High
-
52W Low
-
RSI
-
Rel Volume
51.04
Avg Volume
13.84K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
1.55499
-
-
Volatility
0.37%, 0.37%
Prev Close
-
Price
-
Change
-

NBRV Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
31.9926.115.5715.713.3
Net income per share
-564.91-278.86-135.23-28.52-21.32
Operating cash flow per share
-357.92-242.23-138.83-34.35-13.69
Free cash flow per share
-359.05-242.43-139.05-34.36-13.77
Cash per share
503.13290.4180.5327.494.63
Book value per share
337.77139.0664.4930.771.23
Tangible book value per share
337.29138.7664.3330.751.23
Share holders equity per share
337.77139.0664.4930.771.23
Interest debt per share
117.39128.5318.424.112.21
Market cap
74.16M97.94M31.09M25.96M5.07M
Enterprise value
-4.12M46.43M-2.55M-13.67M-2.12M
P/E ratio
-0.65-1.18-0.45-0.53-0.09
Price to sales ratio
11.4112.6410.850.950.14
POCF ratio
-1.02-1.36-0.44-0.44-0.14
PFCF ratio
-1.02-1.36-0.44-0.44-0.14
P/B Ratio
1.082.370.940.491.54
PTB ratio
1.082.370.940.491.54
EV to sales
-0.635.99-0.89-0.5-0.06
Enterprise value over EBITDA
0.04-0.590.040.280.04
EV to operating cash flow
0.06-0.650.040.230.06
EV to free cash flow
0.06-0.650.040.230.06
Earnings yield
-1.55-0.85-2.24-1.9-11.28
Free cash flow yield
-0.98-0.73-2.3-2.29-7.28
Debt to equity
0.350.840.230.151.59
Debt to assets
0.210.370.130.10.16
Net debt to EBITDA
0.690.650.520.820.13
Current ratio
6.115.483.093.591.13
Interest coverage
-859.96-21.81-38.1153.86-73.31
Income quality
0.630.871.031.20.64
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
6.420000
Research and developement to revenue
12.663.415.270.460.4
Intangibles to total assets
00000
Capex to operating cash flow
00000.01
Capex to revenue
-0.04-0.01-0.040-0.01
Capex to depreciation
-0.45-0.08-0.14-0.04-0.97
Stock based compensation to revenue
0.791.261.820.120.06
Graham number
2.07K934.09442.98140.5124.27
ROIC
-1.24-1.05-1.62-0.8-6.18
Return on tangible assets
-1.04-0.88-1.19-0.61-1.8
Graham Net
317.29120.4742.6621.3-2.3
Working capital
90.95M74.53M38.69M57.93M3.5M
Tangible asset value
68.53M41.18M33.06M53.32M3.29M
Net current asset value
66.97M38.33M31.92M52.71M2.63M
Invested capital
0.350.840.230.151.59
Average receivables
5.39M4.06M3.33M8.33M9.75M
Average payables
4.22M3.99M3.78M3.63M4.9M
Average inventory
0341K3.25M10.17M12.09M
Days sales outstanding
301.6129.27498.18171.0168.99
Days payables outstanding
024.37K1.38K121.3769.36
Days of inventory on hand
03.56K2.77K402.78123.57
Receivables turnover
1.212.820.732.135.29
Payables turnover
00.010.273.015.26
Inventory turnover
00.10.130.912.95
ROE
-1.67-2.01-2.1-0.93-17.37
Capex per share
-1.13-0.21-0.22-0.01-0.08

Quarterly Fundamentals Overview

Last date of statement is 2023-03-31 for Q1

Metric History 2022-03-312022-06-302022-09-302022-12-31 2023-03-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
3.263.473.213.892.37
Net income per share
-5.03-4.38-4.21-8.49-2.85
Operating cash flow per share
-6.75-5.15-2.26-0.61-1.75
Free cash flow per share
-6.76-5.18-2.3-0.61-1.76
Cash per share
14.377.925.364.630.56
Book value per share
18.9813.689.381.23-1.36
Tangible book value per share
18.9713.689.371.23-1.36
Share holders equity per share
18.9813.689.381.23-1.36
Interest debt per share
3.542.92.320.23
Market cap
24.69M11.51M5.68M5.07M5.59M
Enterprise value
-977.47K-1.4M-2.83M-2.12M4.34M
P/E ratio
-0.52-0.26-0.12-0.06-0.15
Price to sales ratio
3.221.310.650.490.74
POCF ratio
-1.56-0.88-0.92-3.12-1
PFCF ratio
-1.55-0.88-0.91-3.1-0.99
P/B Ratio
0.550.330.221.54-1.28
PTB ratio
0.550.330.221.54-1.28
EV to sales
-0.13-0.16-0.32-0.20.57
Enterprise value over EBITDA
0.090.130.260.1-0.51
EV to operating cash flow
0.060.110.461.31-0.77
EV to free cash flow
0.060.110.451.3-0.77
Earnings yield
-0.48-0.96-2.03-4.49-1.63
Free cash flow yield
-0.64-1.14-1.1-0.32-1.01
Debt to equity
0.180.210.241.59-0.12
Debt to assets
0.120.130.130.160.02
Net debt to EBITDA
2.31.240.790.320.15
Current ratio
4.012.812.21.130.85
Interest coverage
-53.76-52.52-76.73-160.65-43.69
Income quality
1.341.180.540.070.65
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
0.460.470.460.250.35
Intangibles to total assets
00000
Capex to operating cash flow
000.020.010
Capex to revenue
0-0.01-0.0100
Capex to depreciation
-0.45-0.83-2.78-0.36-0.14
Stock based compensation to revenue
0.130.040.060.010.13
Graham number
46.3236.7129.8115.329.34
ROIC
-0.23-0.26-0.37-2.662.33
Return on tangible assets
-0.18-0.2-0.24-0.72-0.37
Graham Net
12.26.643.65-2.3-4.53
Working capital
48.93M34.96M25.92M3.5M-4.3M
Tangible asset value
44.6M34.59M25.62M3.29M-4.36M
Net current asset value
44.04M34.01M24.95M2.63M-5M
Invested capital
0.180.210.241.59-0.12
Average receivables
11.88M11.68M12.37M9.57M8.63M
Average payables
2.98M1.33M2.48M4.66M6.2M
Average inventory
15.07M15.58M16.43M13.5M9.35M
Days sales outstanding
129.17126.77126.9358.13124.62
Days payables outstanding
42.2621.6879.3829.9141.51
Days of inventory on hand
418.59313.84353.2553.27183.06
Receivables turnover
0.70.710.711.550.72
Payables turnover
2.134.151.133.010.64
Inventory turnover
0.220.290.251.690.49
ROE
-0.26-0.32-0.45-6.922.09
Capex per share
-0.01-0.03-0.0400

NBRV Frequently Asked Questions

What is Nabriva Therapeutics plc stock symbol ?

Nabriva Therapeutics plc is a IE stock and trading under the symbol NBRV

Is Nabriva Therapeutics plc buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $1. The lowest prediction is $1 and the highest is $1

What is NBRV stock prediction ?

What is Nabriva Therapeutics plc stock quote today ?

Nabriva Therapeutics plc stock price is $- today.

Is Nabriva Therapeutics plc stock public?

Yes, Nabriva Therapeutics plc is a publicly traded company.

Something similar

Top by Market Cap
Same Sector
Check Those
Similar Market Cap